Patel Chem Specialities FY26: Revenue Up 31%, Cash Up 57x, and an EPS That Fell While Profit Rose

General information and entertainment, not investment advice. The author is not a SEBI-registered adviser or research analyst. No recommendation, no promised returns. Markets carry risk including loss of capital. Figures may not be current. Consult a registered adviser before acting.

1 — At a Glance

Patel Chem Specialities closed FY26 with revenue of ₹137.26 Cr, up from ₹105.09 Cr — a 30.6% jump. Net profit rose to ₹12.55 Cr from ₹10.57 Cr. So far, a clean growth story for a cellulose-excipient maker most people have never heard of.

Then the details start arguing with each other. Operating margin slipped from 15% to 12% even as sales climbed. Reported EPS fell — ₹5.91 to ₹5.05 — while profit went up. Cash on the balance sheet went from ₹0.64 Cr to ₹36.59 Cr, a 57-fold leap that has nothing to do with the excipient business and everything to do with an IPO. And ₹35.89 Cr of that pile is sitting in a fixed deposit, earmarked and unspent.

A company that raised ₹55.8 Cr, listed in August 2025, and now carries more cash than it earned in three years of profit combined. The interesting question isn’t how much it grew. It’s what all that idle money is waiting for.

2 — Introduction

Patel Chem was incorporated in 2008 and spent most of its life as a small Ahmedabad chemicals outfit before hitting the BSE SME board on 1 August 2025. The IPO was a fresh issue of ₹55.8 Cr, split between capital expenditure and general corporate purposes.

The money arrived with a plan attached. The company is building a greenfield facility at Indrad, Mehsana, to add 6,012 MTPA to its existing 3,720 MTPA — a capacity roughly tripling if completed. In September 2025 it signed a ₹45 Cr turnkey agreement with J & H Pharma Consultants for the Indrad plant, and had already received environmental clearance for an API project there costing ₹19.75 Cr.

The FY26 results were audited by Parikh Shah & Associates with an unmodified opinion and approved by the board on 22 May 2026. A three-facility manufacturer mid-expansion, freshly capitalised, still small enough that one good year moves every ratio. That’s the setup.

3 — Business Model: WTF Do They Even Do?

Patel Chem makes cellulose-based excipients — the unglamorous ingredients that hold a tablet together and let it dissolve on cue. Its products act as binders, disintegrants, thickeners, stabilizers, and gelling agents, sold under names like Rheollose (sodium CMC), Disolwell (croscarmellose sodium), Swellcal (calcium CMC), and AmyloTab (pregelatinized starch). If you’ve swallowed a pill, something like this made it swallowable.

The naming department clearly had more fun than the product managers. Trademark symbols on four excipients is a level of branding confidence usually reserved for products consumers can actually see.

The end-markets are less pharma than the “pharmaceutical excipients” label suggests. Per the DRHP bifurcation, cosmetics took 63.5% of revenue, food 28.5%, industrial 5%, and pharmaceuticals just 3%. Sodium CMC alone was 27% of product revenue, SMCA 24%, MCC 18%. Manufacturing runs from Vatva, Ahmedabad (the CMC and disintegrant products) and Talod, Himmatnagar (dedicated to MCC).

Geographically it’s an India story with an export garnish: 84% domestic, 16% exports across the USA, Germany, UK, Japan and others. The customer base is over 350 accounts globally, with the top 10 contributing 34% of revenue — concentrated, but not dangerously so.

Does a 3%-pharma “pharma excipient” company get a pharma multiple, or a cosmetics-thickener one? The market is deciding.

4 — Financials Overview

Figures are consolidated, in ₹ crore. With the quarterly block empty, this is a half-yearly reporter, and the latest reported period is H2 FY26 (the six months ended March 2026).

Two things stand out. Revenue in the second half (₹61.16 Cr) was smaller than the first half (₹76.11 Cr)